

Contents

1	The Need for New Agents	1
	Tim Eden	
2	Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia	25
	Shekhar Krishnan, Ashish Masurekar, and Vaskar Saha	
3	Preclinical Evaluation	39
	Barbara Szymanska, Hernan Carol, and Richard B. Lock	
4	Design of Early-Phase Trials	61
	James A. Whitlock and Terzah M. Horton	
5	Strategies for Trial Design and Analyses	83
	Maria Grazia Valsecchi and Paola De Lorenzo	
6	An Overview on Animal Models of ALL	105
	Michael A. Batey and Josef H. Vormoor	
7	Targeting Bcl-2 Family Proteins in Childhood Leukemia	117
	Guy Makin and Caroline Dive	
8	Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL	143
	Clare Pridans and Brian J.P. Huntly	
9	Nucleoside Analogues	167
	Pamela Kearns and Vaskar Saha	
10	FLT3 Inhibitors as Therapeutic Agents in <i>MLL</i> Rearranged Acute Lymphoblastic Leukemia	189
	Ronald W. Stam and Rob Pieters	

11	The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL	203
	S. Wilson	
12	Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia	221
	Arend von Stackelberg	
13	Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia	273
	Joya Chandra and Claudia P. Miller	
14	Targeting Epigenetic Pathways in ALL	299
	Pamela Kearns	
15	Incorporating New Therapies into Frontline Protocols	311
	Paul S. Gaynon and Theresa M. Harned	
	Index.....	329

New Agents for the Treatment of Acute Lymphoblastic
Leukemia

Saha, V.; Kearns, P. (Eds.)

2011, XVIII, 338 p. With 1 4-page color insert.,

Hardcover

ISBN: 978-1-4419-8458-6